Our top pick for
24/5 trading
Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$59.22. During the previous open market day, the price has varied from a low of USD58.955 to a high of USD59.535. Bristol-Myers Squibb Company is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Bristol-Myers Squibb Company
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Bristol-Myers Squibb Company. Find the share by name or ticker symbol: BMY. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bristol-Myers Squibb Company reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$59.22, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Bristol-Myers Squibb Company, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Bristol-Myers Squibb Company. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Have Bristol-Myers Squibb Company's shares ever split?
Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before the split, the next day you would own 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.
Bristol-Myers Squibb Company shares at a glance
Information last updated 2024-11-27.
| 52-week range | US$38.6043 - US$61.08 |
|---|---|
| 50-day moving average | US$54.0176 |
| 200-day moving average | US$48.6253 |
| Target price | US$59.6418 |
| PE ratio | N/A |
| Dividend yield | US$2.4 (4.09%) |
| Earnings per share (TTM) | US$-3.58 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Bristol-Myers Squibb Company price performance over time
Historical closes compared with the last close of $59.22
| 1 week (2024-11-22) | 0.59% |
|---|---|
| 1 month (2024-11-01) | 9.02% |
| 3 months (2024-08-30) | 18.56% |
| 6 months (2024-05-31) | 44.12% |
| 1 year (2023-12-01) | 18.20% |
|---|---|
| 2 years (2022-12-01) | -26.78% |
| 3 years (2021-12-01) | 7.77% |
| 5 years (2019-11-29) | 4.00% |
Compare trading platforms to buy Bristol-Myers Squibb Company shares
1 - 5 of 26
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy Bristol-Myers Squibb Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Bristol-Myers Squibb Company under- or over-valued?
Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb Company's PEG ratio
Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0526. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bristol-Myers Squibb Company's EBITDA
Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$19.2 billion (£15.1 billion).
The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure stock profitability.
Bristol-Myers Squibb Company share price volatility
Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as US$38.6043 up to US$61.08. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.441. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).
Bristol-Myers Squibb Company financials
| Revenue TTM | US$47.4 billion |
|---|---|
| Operating margin TTM | 18.48% |
| Gross profit TTM | US$36.4 billion |
| Return on assets TTM | 6.07% |
| Return on equity TTM | -31.33% |
| Profit margin | -15.3% |
| Book value | 8.453 |
| Market capitalisation | US$120.2 billion |
| EBITDA | US$19.2 billion |
TTM: trailing 12 months
Bristol-Myers Squibb Company share dividends
Dividend payout ratio: 2.26% of net profits
Recently Bristol-Myers Squibb Company has paid out, on average, around 2.26% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.09% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 4.09% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.4 per share.
While Bristol-Myers Squibb Company's payout ratio might seem low, this can signify that Bristol-Myers Squibb Company is investing more in its future growth.
Bristol-Myers Squibb Company's most recent dividend payout was on 31 October 2024. The latest dividend was paid out to all shareholders who bought their shares by 3 October 2024 (the "ex-dividend date").
Bristol-Myers Squibb Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Bristol-Myers Squibb Company's total ESG risk score
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Bristol-Myers Squibb Company's environmental score
Environmental score: 3.83/100
Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's social score
Social score: 18.82/100
Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bristol-Myers Squibb Company's governance score
Governance score: 14.02/100
Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.16 |
|---|---|
| Total ESG percentile | 52.58 |
| Environmental score | 3.83 |
| Environmental score percentile | 4 |
| Social score | 18.82 |
| Social score percentile | 4 |
| Governance score | 14.02 |
| Governance score percentile | 4 |
| Level of controversy | 2 |
Bristol-Myers Squibb Company overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company in the news
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
AbbVie Stock Slides on Schizophrenia Drug Study Failure
Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t
Frequently asked questions
More resources on Finder
More guides on Finder
-
Betashares Direct review
Pay zero brokerage when you invest in ASX ETFs using Betashares Direct.
-
The best ASX penny stocks (updated weekly)
Big gainers included Gratifii, AVJennings and Paradigm Biopharmaceuticals.
-
Best performing stocks on the ASX (Updated weekly)
Top gainers included Gentrack Group, Life360, Inc. and Opthea.
-
How to buy NVIDIA (NVDA) shares in Australia
Steps to owning and managing NVIDIA shares from in Australia.
-
Fixed-income investments in Australia
Looking for fixed-income investments in Australia? Compare platforms to start investing in funds, bonds, hybrid securities, P2P and more.
-
Invest in renewable energy stocks
Start here if you want to buy sustainable energy shares on the ASX.
-
What are franking credits in Australia?
Franking credits get a lot of attention but how do they impact shareholders during tax time and why do they exist?
-
What is risk profiling and how does it work?
What is risk profiling in financial planning and how does your risk profile influence where you invest your money? Find out in this handy guide.
-
Passive investing in Australia
Passive investing is a hands-off approach to investing in assets that require little active involvement, such as dividend stocks, ETFs and property.
-
CMC Invest review for Australia
CMC Invest account features brokerage from as low as $9.90 and a host of research and market data options.
Ask a question